JP2008517613A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517613A5
JP2008517613A5 JP2007538421A JP2007538421A JP2008517613A5 JP 2008517613 A5 JP2008517613 A5 JP 2008517613A5 JP 2007538421 A JP2007538421 A JP 2007538421A JP 2007538421 A JP2007538421 A JP 2007538421A JP 2008517613 A5 JP2008517613 A5 JP 2008517613A5
Authority
JP
Japan
Prior art keywords
jak2
variant
sequence
seq
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007538421A
Other languages
English (en)
Japanese (ja)
Other versions
JP5090171B2 (ja
JP2008517613A (ja
Filing date
Publication date
Priority claimed from FR0411480A external-priority patent/FR2877013A1/fr
Application filed filed Critical
Publication of JP2008517613A publication Critical patent/JP2008517613A/ja
Publication of JP2008517613A5 publication Critical patent/JP2008517613A5/ja
Application granted granted Critical
Publication of JP5090171B2 publication Critical patent/JP5090171B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007538421A 2004-10-27 2005-10-26 真性赤血球増加症に関与するｊａｋ２の変異の識別方法 Expired - Lifetime JP5090171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0411480 2004-10-27
FR0411480A FR2877013A1 (fr) 2004-10-27 2004-10-27 Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
PCT/EP2005/055586 WO2006045827A1 (fr) 2004-10-27 2005-10-26 Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009155912A Division JP5290884B2 (ja) 2004-10-27 2009-06-30 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Publications (3)

Publication Number Publication Date
JP2008517613A JP2008517613A (ja) 2008-05-29
JP2008517613A5 true JP2008517613A5 (enExample) 2009-03-05
JP5090171B2 JP5090171B2 (ja) 2012-12-05

Family

ID=34953071

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007538421A Expired - Lifetime JP5090171B2 (ja) 2004-10-27 2005-10-26 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP2009155912A Expired - Lifetime JP5290884B2 (ja) 2004-10-27 2009-06-30 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP2013003374A Expired - Lifetime JP6103691B2 (ja) 2004-10-27 2013-01-11 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009155912A Expired - Lifetime JP5290884B2 (ja) 2004-10-27 2009-06-30 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP2013003374A Expired - Lifetime JP6103691B2 (ja) 2004-10-27 2013-01-11 真性赤血球増加症に関与するｊａｋ２の変異の識別方法

Country Status (20)

Country Link
US (9) US7781199B2 (enExample)
EP (2) EP1895000A1 (enExample)
JP (3) JP5090171B2 (enExample)
KR (1) KR101203003B1 (enExample)
CN (1) CN101072870B (enExample)
AT (1) ATE382082T1 (enExample)
AU (1) AU2005298636B2 (enExample)
BR (1) BRPI0517398B8 (enExample)
CA (3) CA2647086C (enExample)
DE (1) DE602005004008T2 (enExample)
DK (1) DK1692281T3 (enExample)
ES (1) ES2296229T3 (enExample)
FR (1) FR2877013A1 (enExample)
IL (1) IL182761A0 (enExample)
MX (1) MX2007005174A (enExample)
PL (1) PL1692281T3 (enExample)
PT (1) PT1692281E (enExample)
SI (1) SI1692281T1 (enExample)
WO (1) WO2006045827A1 (enExample)
ZA (1) ZA200703433B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
CN100497657C (zh) * 2006-09-27 2009-06-10 北京大学人民医院 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针
US20080153097A1 (en) * 2006-11-15 2008-06-26 Eragen Biosciences, Inc. Methods and kits for detecting jak2 nucleic acid
US8367078B2 (en) * 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
EP2119796B1 (en) * 2007-07-13 2014-01-15 ARKRAY, Inc. Probe for detecting mutation in jak2 gene and use thereof
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2272978B1 (en) 2009-07-10 2012-04-18 Biotrin International Limited Highly sensitive rapid isothermal method for the detection of point mutations and SNPs
WO2011067373A1 (fr) * 2009-12-04 2011-06-09 Assistance Publique - Hopitaux De Paris Methode de detection d'une polyglobulie chez un chien
CA2789186A1 (en) * 2010-02-10 2011-08-18 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
US20120021413A1 (en) * 2010-04-30 2012-01-26 Arkray, Inc. Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor
JP6076901B2 (ja) * 2010-07-16 2017-02-15 スティヒティング フェーユーエムセー 被験者の血液サンプル中の疾患マーカーの存在の分析方法
SG193539A1 (en) 2011-03-18 2013-10-30 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg A method of analysing a blood sample of a subject for the presence of a disease marker
JP2013017395A (ja) * 2011-07-07 2013-01-31 Toyobo Co Ltd 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法
GB201116876D0 (en) * 2011-09-30 2011-11-16 Epistem Ltd Mutational analysis of JAK2
CN103243153B (zh) * 2012-02-10 2014-11-05 复旦大学附属华山医院 Jak2 v617f突变的检测应用
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
US9523084B2 (en) 2012-11-08 2016-12-20 Centre National De La Recherche Scientifique (Cnrs) Phosphodeoxyribosyl transferase mutant enzymes and uses thereof
CA2890658A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
PT3456333T (pt) 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG11201509556TA (en) 2013-05-16 2015-12-30 Mobelisk Llc Modular tablet case
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016168612A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
US10519509B2 (en) 2015-04-23 2019-12-31 Quest Diagnostics Investments Incorporated Methods and compositions for the detection of CALR mutations in myeloproliferative diseases
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN105441573A (zh) * 2016-01-11 2016-03-30 武汉海吉力生物科技有限公司 用于检测人类jak2基因v617f突变的引物、探针及试剂盒
CN109803674A (zh) * 2016-06-10 2019-05-24 Io生物技术公司 Calr和jak2疫苗组合物
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
WO2026136827A1 (en) * 2024-12-20 2026-06-25 Incyte Corporation Treatment of clonal hematopoietic disorders using kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
WO1997003358A1 (en) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
US5914393A (en) * 1995-12-05 1999-06-22 Incyte Pharmaceuticals, Inc. Human Jak2 kinase
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
EP1056889B1 (en) 1998-09-25 2007-06-27 Massachusetts Institute Of Technology Methods related to genotyping and dna analysis
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
IL153426A0 (en) * 2000-06-30 2003-07-06 Pfizer Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds
US20050235375A1 (en) * 2001-06-22 2005-10-20 Wenqiong Chen Transcription factors of cereals
AU2003299467A1 (en) 2002-05-03 2004-08-10 Gene Logic, Inc. Canine gene microarrays
CA2491637A1 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
EP1572957A4 (en) * 2002-08-27 2007-10-10 Bristol Myers Squibb Pharma Co IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS INTERACTING WITH AND / OR MODULATING TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS IN MAMMARY CELLS
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US7514229B2 (en) * 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US20070248961A1 (en) * 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid
EP2525651A4 (en) * 2010-01-22 2013-12-11 Chromatin Inc NEW CENTROMERE AND METHOD FOR THEIR USE

Similar Documents

Publication Publication Date Title
AU2011312504B2 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
JP6103691B2 (ja) 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JP6219824B2 (ja) びまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）患者における抗−ｃｄ２０療法に対する応答の予測
JP6216486B2 (ja) 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法
US20170114417A1 (en) Pkn1 fusions
JPWO2012157684A1 (ja) 血中ｄｎａの定量的検出による悪性新生物の病勢の進行を評価する方法
KR102885025B1 (ko) 유전적 조절
US20150218651A1 (en) Use of dna in circulating exosomes as a diagnostic marker for metastatic disease
JP2014082984A (ja) 新規ｎｔｒｋ２活性化変異の検出法
CA2980393A1 (en) Methods for diagnosing and treating follicular lymphoma
AU2015332624A1 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
US20240131050A1 (en) Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
US20170058361A1 (en) Polypeptides and Antibodies for Assessing Predisposition for Myelodysplastic Syndromes or Myelogenous Tumor, and Method for Screening Therapeutic Drugs Therefor
JP2013226108A (ja) 新規ｎｔｒｋ２活性化変異の検出法
WO2016042114A1 (en) Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis
JP6449147B2 (ja) Ｔ細胞リンパ腫の検出方法
CN113981071B (zh) Csf1r相关基因突变作为诊断cvm的标志物及其应用
KR20190086569A (ko) 암 진단에서 후생적 염색체 상호 작용의 적용
TWI479024B (zh) 檢測ｐ／ｐ血型的方法及其檢測套組
JP2008504838A (ja) Ｐｒｋｃｂ１をコードするヒト自閉症感受性遺伝子およびその使用
Shoukier et al. Characterization of five novel large deletions causing hereditary haemorrhagic telangiectasia
JP6017117B2 (ja) 炎症性腸疾患患者におけるアザチオプリン（ａｚｔ）の血中濃度の安定性を予測するジェネティックバイオマーカー
KR101683961B1 (ko) 방광암 재발 진단 마커
CN108251519B (zh) 轴前多指病的致病基因及其用途
HK1234445A (en) Ncrna and uses thereof